Physician
Steward ST. Annes Hospital Corporation
Steward ST. Annes Hospital Corporation was paid $82.71M by Medicaid between Jan 2018 and Sep 2024, across 388 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoSTEWARD ST. ANNES HOSPITAL CORPORATION
FALL RIVER, MA 02721
FALL RIVER, MA 02721
33aNPI1932411493assigned 07/12/2010
33bProvider typePlastic and Reconstructive Surgery Physician
28Total paid$82.71M
24GClaims1,698,678
24DCodes billed388
24AFirst – last monthJan 2018 – Sep 2024
Compared with peers
Next to other Plastic and Reconstructive Surgery Physician providers in Massachusetts
Rank by total paid#1 of 8
Median peer was paid$2K
This provider vs. median35,666×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOYLE, JOHN controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 284,258 | $16.65M | |
| 2019 | 276,750 | $13.18M | |
| 2020 | 241,843 | $9.79M | |
| 2021 | 275,070 | $11.85M | |
| 2022 | 252,679 | $11.96M | |
| 2023 | 223,781 | $11.30M | |
| 2024incomplete | 144,297 | $7.97M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 61,158 | 55,652 | $9.05M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.1% | 24,553 | 19,748 | $7.55M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 7.8% | 46,047 | 42,936 | $6.43M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.5% | 43,465 | 39,591 | $6.17M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.0% | 41,183 | 35,650 | $5.82M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 3.5% | 4,339 | 4,245 | $2.88M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.5% | 5,599 | 5,423 | $2.87M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 2.5% | 2,762 | 2,676 | $2.09M |
| 62323 | 2.2% | 4,937 | 4,789 | $1.78M | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.0% | 63,647 | 58,589 | $1.63M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.8% | 9,174 | 8,902 | $1.53M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 10,399 | 9,800 | $1.48M |
376 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 9,867 | $1.45M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 11,530 | $1.31M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 12,756 | $1.31M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.4% | 2,242 | $1.15M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 25,645 | $1.09M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 10,335 | $1.09M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.2% | 8,004 | $1.01M |
| 64493 | <1% | 1,796 | $753K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 948 | $722K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 7,832 | $708K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,460 | $704K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12,214 | $654K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,057 | $654K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 7,262 | $580K |
| 64483 | <1% | 1,581 | $580K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 3,173 | $564K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,896 | $561K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,932 | $556K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,217 | $551K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 866 | $550K |
| 20610 | <1% | 4,288 | $527K | |
| 43235 | <1% | 1,035 | $469K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 95,984 | $445K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,826 | $437K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,939 | $390K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,140 | $375K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,508 | $366K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,442 | $353K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,989 | $351K |
| G0378 | Hospital observation service, per hour | <1% | 11,218 | $342K |
| 62321 | <1% | 839 | $335K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,351 | $332K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 24,813 | $323K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 237 | $318K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 420 | $316K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 462 | $274K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 7,187 | $258K |
| 72141 | <1% | 1,325 | $252K | |
| 29848 | <1% | 173 | $244K | |
| 93971 | <1% | 1,697 | $233K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 887 | $233K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 7,613 | $225K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 11,770 | $211K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,474 | $201K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,841 | $191K |
| 73221 | <1% | 929 | $191K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,146 | $190K |
| 96367 | <1% | 5,025 | $187K | |
| 87428 | <1% | 3,634 | $183K | |
| 96415 | <1% | 1,208 | $179K | |
| 80053 | Comprehensive metabolic panel | <1% | 46,996 | $171K |
| 76770 | <1% | 1,420 | $170K | |
| 84484 | <1% | 26,363 | $160K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,745 | $159K |
| 95811 | <1% | 207 | $154K | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 147 | $145K |
| 97161 | <1% | 3,016 | $144K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,462 | $140K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,312 | $136K |
| ATP14 | <1% | 15,553 | $131K | |
| 81025 | <1% | 20,485 | $127K | |
| J2704 | Injection, propofol, 10 mg | <1% | 33,956 | $125K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 27,766 | $125K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 47,303 | $124K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 48 | $119K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 40,200 | $116K |
| 12001 | <1% | 555 | $110K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 46,900 | $108K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,654 | $107K |
| 76642 | <1% | 1,120 | $107K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,102 | $106K |
| 74183 | <1% | 640 | $103K | |
| 92526 | <1% | 1,115 | $102K | |
| 20552 | <1% | 789 | $94K | |
| ATP08 | <1% | 13,667 | $93K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,592 | $91K |
| 20553 | <1% | 768 | $90K | |
| 77412 | <1% | 719 | $90K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 15,171 | $90K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,000 | $89K |
| 82947 | <1% | 25,174 | $79K | |
| 77336 | <1% | 1,613 | $79K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 33,847 | $78K |
| 83690 | <1% | 15,641 | $77K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 20,108 | $77K |
| 64484 | <1% | 549 | $72K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 19,274 | $70K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 9,861 | $69K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,714 | $69K |
| 93270 | <1% | 1,775 | $69K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,719 | $67K |
| 64494 | <1% | 2,289 | $66K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 19,026 | $64K |
| 97165 | <1% | 996 | $63K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,565 | $62K |
| 82805 | <1% | 2,187 | $61K | |
| 88342 | <1% | 6,578 | $61K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,367 | $61K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,998 | $59K |
| 97802 | <1% | 1,040 | $58K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,252 | $58K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,769 | $56K |
| ATP15 | <1% | 6,855 | $56K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,149 | $55K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 891 | $53K |
| 83735 | <1% | 12,849 | $53K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,795 | $52K |
| 84600 | <1% | 4,690 | $52K | |
| 73610 | <1% | 3,333 | $50K | |
| 81001 | <1% | 20,392 | $50K | |
| 82728 | <1% | 8,293 | $49K | |
| 72100 | <1% | 2,006 | $49K | |
| 73630 | <1% | 3,498 | $48K | |
| 92523 | <1% | 366 | $47K | |
| 78264 | <1% | 206 | $46K | |
| 84703 | <1% | 8,047 | $44K | |
| 84466 | <1% | 7,734 | $44K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,312 | $43K |
| 73130 | <1% | 2,844 | $41K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 487 | $40K |
| 71250 | <1% | 903 | $39K | |
| 83880 | <1% | 2,943 | $38K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 20,858 | $38K |
| 87040 | <1% | 5,290 | $36K | |
| 90715 | <1% | 1,805 | $36K | |
| 12011 | <1% | 183 | $36K | |
| 77065 | Tomosynthesis, mammo | <1% | 652 | $36K |
| 73564 | <1% | 2,073 | $33K | |
| 47562 | <1% | 14 | $33K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 536 | $31K |
| 52005 | <1% | 95 | $31K | |
| 73030 | <1% | 2,664 | $30K | |
| 87081 | <1% | 5,505 | $30K | |
| 83615 | <1% | 8,945 | $29K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,070 | $29K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 9,847 | $29K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,398 | $29K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,002 | $28K |
| 84702 | <1% | 2,383 | $28K | |
| 87186 | <1% | 3,815 | $28K | |
| 97162 | <1% | 732 | $28K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 96 | $27K |
| 27096 | <1% | 30 | $27K | |
| 80076 | <1% | 10,858 | $27K | |
| 26055 | <1% | 27 | $27K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 20,025 | $26K |
| 83540 | <1% | 8,220 | $26K | |
| 88341 | <1% | 1,269 | $26K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,546 | $26K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 8,251 | $25K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,931 | $25K |
| 83605 | <1% | 4,237 | $24K | |
| 76536 | <1% | 267 | $23K | |
| 73110 | <1% | 1,526 | $23K | |
| Q3014 | Telehealth originating site facility fee | <1% | 9,854 | $22K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 155 | $22K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 6,009 | $21K |
| 93970 | <1% | 144 | $21K | |
| 85027 | <1% | 5,873 | $21K | |
| 81003 | <1% | 11,948 | $20K | |
| 93017 | <1% | 220 | $18K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 137 | $18K |
| 85610 | <1% | 7,770 | $18K | |
| 10060 | <1% | 105 | $17K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,844 | $17K |
| 82607 | <1% | 2,230 | $16K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,573 | $16K |
| 97035 | <1% | 386 | $16K | |
| 87070 | <1% | 3,396 | $16K | |
| 80050 | General health panel | <1% | 1,042 | $16K |
| 64495 | <1% | 455 | $15K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 206 | $15K |
| 77334 | <1% | 183 | $15K | |
| 85379 | <1% | 2,325 | $15K | |
| 74018 | <1% | 848 | $15K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 328 | $14K |
| 77002 | <1% | 191 | $14K | |
| 74246 | <1% | 109 | $14K | |
| 97010 | <1% | 311 | $13K | |
| 85007 | <1% | 5,033 | $13K | |
| C1769 | Guide wire | <1% | 1,485 | $13K |
| 86850 | <1% | 2,352 | $13K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,014 | $12K |
| 93458 | <1% | 12 | $12K | |
| 88304 | <1% | 2,084 | $12K | |
| 88307 | <1% | 244 | $11K | |
| 87077 | <1% | 2,350 | $11K | |
| 85730 | <1% | 3,535 | $11K | |
| 64490 | <1% | 16 | $11K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,994 | $11K |
| 73140 | <1% | 598 | $11K | |
| 73562 | <1% | 1,016 | $10K | |
| 72131 | <1% | 389 | $10K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 716 | $10K |
| 74247 | <1% | 55 | $10K | |
| 64635 | <1% | 12 | $9K | |
| 87205 | <1% | 2,807 | $9K | |
| 97166 | <1% | 174 | $9K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 206 | $9K |
| 82378 | <1% | 1,291 | $8K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,112 | $8K |
| 87147 | <1% | 874 | $8K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,272 | $8K |
| 73502 | <1% | 850 | $7K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 60 | $7K |
| 82746 | <1% | 1,142 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,609 | $7K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 45 | $7K |
| 86901 | <1% | 2,434 | $6K | |
| ATP16 | <1% | 1,085 | $6K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 231 | $6K |
| 86900 | <1% | 2,439 | $6K | |
| 77300 | <1% | 90 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 260 | $6K |
| 80179 | <1% | 1,046 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,440 | $5K |
| 80143 | <1% | 1,109 | $5K | |
| 73080 | <1% | 418 | $5K | |
| 97803 | <1% | 78 | $5K | |
| 77080 | <1% | 119 | $5K | |
| 74019 | <1% | 110 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,884 | $5K |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 67 | $5K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,015 | $5K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,473 | $5K |
| 64615 | <1% | 26 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,040 | $4K |
| 82565 | <1% | 2,319 | $4K | |
| 64450 | <1% | 25 | $4K | |
| 96376 | <1% | 3,498 | $4K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,272 | $4K |
| 74420 | <1% | 518 | $4K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,524 | $4K |
| 70486 | <1% | 73 | $3K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 34 | $3K |
| 88313 | <1% | 2,139 | $3K | |
| 76870 | <1% | 31 | $3K | |
| 76801 | <1% | 13 | $3K | |
| 82140 | <1% | 459 | $3K | |
| 64491 | <1% | 16 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,851 | $3K |
| J3490 | Unclassified drugs | <1% | 105 | $3K |
| 87486 | <1% | 113 | $3K | |
| 93272 | <1% | 208 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 70 | $3K |
| 86300 | <1% | 283 | $3K | |
| 70544 | <1% | 30 | $3K | |
| 87088 | <1% | 397 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,546 | $2K |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | <1% | 116 | $2K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 15 | $2K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 28 | $2K |
| 82784 | <1% | 230 | $2K | |
| 84439 | <1% | 535 | $2K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 542 | $2K |
| 87808 | <1% | 120 | $2K | |
| 74220 | <1% | 52 | $2K | |
| 87807 | <1% | 168 | $2K | |
| 84100 | <1% | 1,644 | $2K | |
| 12002 | <1% | 13 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 77 | $2K |
| 84550 | <1% | 2,511 | $2K | |
| 70496 | <1% | 43 | $2K | |
| ATP02 | <1% | 1,228 | $2K | |
| 98927 | <1% | 104 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,589 | $2K |
| 83883 | <1% | 228 | $2K | |
| 84153 | <1% | 296 | $2K | |
| 92610 | <1% | 14 | $1K | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 214 | $1K |
| 87476 | <1% | 72 | $1K | |
| 82010 | <1% | 291 | $1K | |
| 82232 | <1% | 131 | $1K | |
| 76942 | <1% | 41 | $1K | |
| 90674 | <1% | 210 | $1K | |
| 97597 | <1% | 37 | $1K | |
| 77470 | <1% | 14 | $1K | |
| 74178 | <1% | 12 | $1K | |
| 85652 | <1% | 900 | $1K | |
| 83550 | <1% | 353 | $1K | |
| 84165 | <1% | 229 | $1K | |
| C1781 | Mesh (implantable) | <1% | 12 | $1K |
| 86317 | <1% | 42 | $990.18 | |
| 73590 | <1% | 69 | $981.27 | |
| 85014 | <1% | 1,593 | $955.34 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 855 | $933.06 |
| 85018 | <1% | 1,525 | $902.30 | |
| 88173 | <1% | 12 | $869.18 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 778 | $826.49 |
| 70491 | <1% | 16 | $823.95 | |
| 84450 | <1% | 252 | $755.54 | |
| 86618 | <1% | 67 | $743.12 | |
| 98928 | <1% | 29 | $680.67 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 937 | $675.27 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 630 | $646.43 |
| 86140 | <1% | 296 | $636.57 | |
| 88312 | <1% | 455 | $628.23 | |
| 36591 | <1% | 414 | $582.42 | |
| 71101 | <1% | 94 | $574.69 | |
| 84145 | <1% | 43 | $492.73 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,184 | $482.07 |
| 88112 | <1% | 14 | $476.28 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,013 | $463.28 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 228 | $457.64 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 15 | $448.21 |
| 97116 | <1% | 70 | $437.50 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,896 | $435.24 |
| 83921 | <1% | 69 | $426.98 | |
| 85045 | <1% | 222 | $358.96 | |
| 73090 | <1% | 42 | $346.07 | |
| 83520 | <1% | 99 | $309.62 | |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $296.60 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 303 | $279.44 |
| ATP09 | <1% | 35 | $272.70 | |
| 90714 | <1% | 20 | $264.24 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 323 | $262.38 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 13 | $252.13 |
| 96417 | <1% | 820 | $249.39 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 186 | $224.33 |
| 72070 | <1% | 13 | $221.72 | |
| 84460 | <1% | 239 | $204.94 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 126 | $184.10 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 126 | $171.27 |
| 80061 | Lipid panel | <1% | 219 | $166.72 |
| 80320 | <1% | 471 | $137.32 | |
| 85651 | <1% | 65 | $111.78 | |
| ATP10 | <1% | 14 | $107.52 | |
| 82550 | <1% | 147 | $107.43 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,062 | $103.28 |
| ATP03 | <1% | 60 | $75.35 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 33 | $68.75 |
| 72020 | <1% | 409 | $68.10 | |
| 77417 | <1% | 50 | $63.35 | |
| 85041 | <1% | 42 | $55.20 | |
| G0008 | Administration of influenza virus vaccine | <1% | 119 | $50.06 |
| 82271 | <1% | 13 | $37.52 | |
| 80178 | <1% | 12 | $30.15 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 149 | $27.02 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 140 | $25.42 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 61 | $24.64 |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 26 | $8.51 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 422 | $5.38 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 67 | $4.86 |
| J1815 | Injection, insulin, per 5 units | <1% | 130 | $2.88 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 67 | $0.56 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 163 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 365 | $0.00 |
| 83521 | 0% | 57 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 14 | $0.00 |
| 80329 | 0% | 45 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 78 | $0.00 |
| 96411 | 0% | 115 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 56 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 113 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 56 | $0.00 |
| 0250 | 0% | 53 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 15 | $0.00 |
| 82040 | 0% | 12 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 364 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 872 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 26 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 498 | $0.00 |
| C1765 | Adhesion barrier | 0% | 85 | $0.00 |
| 84520 | 0% | 103 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 324 | $0.00 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 40 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 49 | $0.00 |
| 64636 | 0% | 19 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 25 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 16 | $0.00 |
| 94729 | 0% | 12 | $0.00 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 0% | 20 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 14 | $0.00 |
| 94060 | 0% | 12 | $0.00 | |
| 43450 | 0% | 14 | $0.00 | |
| 94727 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOYLE, JOHN (CHIEF FINANCIAL OFFICER)
Parent organizationSTEWARD HEALTH CARE SYSTEM LLC
| Provider | Location | Paid |
|---|---|---|
| Steward Trumbull Memorial Hospital, INC. | Warren, OH | $16.49M |
| Steward Sharon Regional Health System, INC. | Sharon, PA | $6.76M |
| Steward Rockledge Hospital, INC. | Rockledge, FL | $6.16M |
| Southwest General Hospital LP | San Antonio, TX | $5.84M |
| Steward Sharon Regional Health System, INC. | Sharon, PA | $5.84M |
| SHC Youngstown Ohio Laboratory Services Company LLC | Poland, OH | $3.41M |
| Steward Melbourne Hospital, INC. | Melbourne, FL | $3.35M |
| Steward Hillside Rehabilitation Hospital, INC. | Warren, OH | $2.74M |
| Steward Sebastian River Medical Center, INC. | Sebastian, FL | $2.16M |
| Steward Northside Medical Center, INC. | Youngstown, OH | $1.58M |
| Steward Rockledge Hospital, INC. | Rockledge, FL | $974K |
| Newberry County EMS | Newberry, SC | $758K |
| Steward Sharon Regional Health System, INC. | Mercer, PA | $181K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.